Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation

Claim 2

A compound of formula III or a therapeutically acceptable salt thereof in which R I and R 2 are the same or different and are hydrogen, alkyl, halogen, methoxycarbonyl, ethoxycarbonyl, alkoxy, or alkanoyl in any position, R 6 is hydrogen, methyl or ethyl, R 3 , R 4 and R 5 are the same or different and are each hydrogen, methyl, methoxy, ethox), methoxyethoxy or ethoxyethoxy, whereby R 3 , R 4 , and R 5 and R 5 are not all hydrogen, and whereby when two of R 3 , R 4 , and R 5 are hydrogen, the third of R 3 , R 4 , and R 5 is not methyl.

Claim 3

A compound according to claim 1, which is 2-[2-(3,4-dimethyl-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(3,5-dimethyl-pyridyl)methylsulfinyl]-4,6-dimethyl-benzimidazole, 2-[2-(4,5-dimethyl-pyridyl)methylsulfinyl]-5-methoxy-carbonyl-benzimidazole, 2-[2-(4,5-dimethyl-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(4,5-dimethyl-pyridyl)methylsulfinyl]-5-methoxy-carbonyl-6-methyl-benzimidazole, 2-[2-(3,4-dimethyl-pyridyl)methylsulfinyl]-5-methoxy-carbonyl-6-methyl-benzimidazole, 2-[2-(3,5-dimethyl-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(3,4,5-trimethyl-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(4-methoxy-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(4-methoxy-pyridyl)methylsulfinyl]-4,6-dimethyl-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-acetyl-6-methyl-benzimidazole, 2-[2-(3,5-dimethyl-pyridyl)methylsulfinyl]-5-methoxy-carbonyl-6-methyl-benzimidazole, 2-[2-(3,4,5-trimethyl-pyridyl)methylsulfinyl-5-methoxy-carbonyl-6-methyl-benzimidazole, 2-[2-(4-methoxy-pyridyl)methylsulfinyl]-5-methoxycarbonyl-6-methyl-benzimidazole, 2-[2-(4-ethoxy-pyridyl)methylsulfinyl]-5-methoxycarbonyl-6-methyl-benzimidazole, 2-[2-(3-methyl-4-methoxy-pyridyl)methylsulfinyl]-5-methoxycarbonyl-6-methyl-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-methoxycarbonyl-6-methylbenzimidazole, 2-[2-(4-methoxy-5-methyl-pyridyl)methylsufinyl]-5-methoxycarbonyl-6-methyl-benzimidazole, 2-[2-(3,5-dimethyl-pyridyl)methylsulfinyl]-5-methoxycarbonyl-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-methoxycarbonyl-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-acetyl-benzimidazole, 2-[2-(4-methoxy-5-methyl-pyridyl)methylsulfinyl]-5-methoxy-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-methoxy-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methy)sulfinyl]-5-methy)-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-benzimidazole, 2-[2-(3,5-dimethyl-4-methoxy-pyridyl)methylsulfinyl]-5-chloro-benzimidazole

Claim 4

A pharmaceutical preparation for inhibiting gastric acid secretion, characterized in that it contains as active agent a compound according to claim 1 or a pharmaceutically acceptable non-toxic acid addition salt thereof in a therapeutically effective amount in combination with a pharmaceutically acceptable carrier.

Claim 5

A pharmaceutical preparation according to claim 3 wherein the active ingredient is one of the compounds according to claim 2.

Claim 6

Intermediates of the formula wherein R I , R 2 , R 3 , R 4 , R 5 and R 6 are defined according to claim 1.